| Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis Nature 476 (7359), 214-219, 2011 | 3008 | 2011 |
| Neurofilaments as biomarkers in neurological disorders M Khalil, CE Teunissen, M Otto, F Piehl, MP Sormani, T Gattringer, ... Nature Reviews Neurology 14 (10), 577-589, 2018 | 1541 | 2018 |
| Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis International IBD Genetics Consortium (IIBDGC), C Agliardi, L Alfredsson, ... Nature genetics 45 (11), 1353-1360, 2013 | 1345 | 2013 |
| Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility International Multiple Sclerosis Genetics Consortium*†, ANZgene, ... Science 365 (6460), eaav7188, 2019 | 922 | 2019 |
| Cortical brain abnormalities in 4474 individuals with schizophrenia and 5098 control subjects via the enhancing neuro imaging genetics through meta analysis (ENIGMA) consortium TGM Van Erp, E Walton, DP Hibar, L Schmaal, W Jiang, DC Glahn, ... Biological psychiatry 84 (9), 644-654, 2018 | 742 | 2018 |
| Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind … JF Howard, K Utsugisawa, M Benatar, H Murai, RJ Barohn, I Illa, S Jacob, ... The Lancet Neurology 16 (12), 976-986, 2017 | 601 | 2017 |
| Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis C Bridel, WN Van Wieringen, H Zetterberg, BM Tijms, CE Teunissen, ... JAMA neurology 76 (9), 1035-1048, 2019 | 573 | 2019 |
| Risk factors for amyotrophic lateral sclerosis C Ingre, PM Roos, F Piehl, F Kamel, F Fang Clinical epidemiology, 181-193, 2015 | 537 | 2015 |
| Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies G Luna, P Alping, J Burman, K Fink, A Fogdell-Hahn, M Gunnarsson, ... JAMA neurology 77 (2), 184-191, 2020 | 441 | 2020 |
| Memory B cells activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis I Jelcic, F Al Nimer, J Wang, V Lentsch, R Planas, I Jelcic, A Madjovski, ... Cell 175 (1), 85-100. e23, 2018 | 441 | 2018 |
| MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction M Swanberg, O Lidman, L Padyukov, P Eriksson, E Åkesson, M Jagodic, ... Nature genetics 37 (5), 486-494, 2005 | 412 | 2005 |
| Monitoring disease activity in multiple sclerosis using serum neurofilament light protein L Novakova, H Zetterberg, P Sundström, M Axelsson, M Khademi, ... Neurology 89 (22), 2230-2237, 2017 | 411 | 2017 |
| Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab M Gunnarsson, C Malmeström, M Axelsson, P Sundström, C Dahle, ... Annals of neurology 69 (1), 83-89, 2011 | 400 | 2011 |
| Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study J Kuhle, G Disanto, R Dobson, R Adiutori, L Bianchi, J Topping, ... Multiple Sclerosis Journal 21 (8), 1013-1024, 2015 | 378 | 2015 |
| Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy J Salzer, R Svenningsson, P Alping, L Novakova, A Björck, K Fink, ... Neurology 87 (20), 2074-2081, 2016 | 377 | 2016 |
| Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells H Hammarberg, O Lidman, C Lundberg, SY Eltayeb, AW Gielen, ... Journal of Neuroscience 20 (14), 5283-5291, 2000 | 371 | 2000 |
| Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open … R Kapoor, PR Ho, N Campbell, I Chang, A Deykin, F Forrestal, N Lucas, ... The Lancet Neurology 17 (5), 405-415, 2018 | 332 | 2018 |
| T Cell Ig-and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived … M Khademi, Z Illés, AW Gielen, M Marta, N Takazawa, C Baecher-Allan, ... The Journal of Immunology 172 (11), 7169-7176, 2004 | 319 | 2004 |
| Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study A He, B Merkel, JWL Brown, LZ Ryerson, I Kister, CB Malpas, S Sharmin, ... The Lancet Neurology 19 (4), 307-316, 2020 | 303 | 2020 |
| Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course M Khademi, I Kockum, ML Andersson, E Iacobaeus, L Brundin, ... Multiple Sclerosis Journal 17 (3), 335-343, 2011 | 298 | 2011 |
